Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 485.26M P/E - EPS this Y - Ern Qtrly Grth -
Income -33.52M Forward P/E -8.50 EPS next Y -26.70% 50D Avg Chg -1.00%
Sales 264.78M PEG -0.11 EPS past 5Y 65.15% 200D Avg Chg -15.00%
Dividend N/A Price/Book 0.85 EPS next 5Y 38.90% 52W High Chg -47.00%
Recommedations 3.70 Quick Ratio 1.87 Shares Outstanding 411.17M 52W Low Chg 14.00%
Insider Own 1.59% ROA -2.02% Shares Float 383.41M Beta 1.93
Inst Own 19.77% ROE -5.98% Shares Shorted/Prior 18.23M/18.61M Price 1.19
Gross Margin 61.29% Profit Margin -12.66% Avg. Volume 2,478,600 Target Price 1.00
Oper. Margin -0.78% Earnings Date Oct 30 Volume 2,150,082 Change 0.00%
About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Amarin Corporation plc News
12/16/24 Amarin Receives National Reimbursement for VAZKEPA® in Italy
12/13/24 Amarin Appoints Peter Fishman Chief Financial Officer
11/19/24 After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
11/11/24 Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
11/01/24 Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...
10/31/24 Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
10/31/24 Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript
10/30/24 Amarin: Q3 Earnings Snapshot
10/30/24 Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
10/09/24 Amarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
10/01/24 Amarin Announces Two Upcoming Investor Events
09/18/24 Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
09/09/24 Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
08/22/24 Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
08/08/24 Exploring 3 Undervalued Small Caps In United States With Insider Action
08/01/24 Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat
07/31/24 Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
07/31/24 Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
07/29/24 3 Breakthrough Stocks Under $10 Set for Massive Upside
07/23/24 Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ketchum Steven B Chief Scientific Off.. Chief Scientific Officer Dec 12 Sell 0.79 34,131 26,963 566,100 12/14/23
Holt Patrick President and CEO President and CEO Aug 16 Buy 1.04 300,000 312,000 300,000 08/16/23
WOLD OLSEN PER Director Director Jun 13 Buy 1.686 55,000 92,730 149,000 06/15/22
STACK DAVID M Director Director Jun 07 Buy 4.58 15,000 68,700 40,000 06/07/21
Ketchum Steven B Chief Scientific Off.. Chief Scientific Officer Feb 03 Option 2.65 192,358 509,749 600,724 02/03/21
Ketchum Steven B Chief Scientific Off.. Chief Scientific Officer Feb 03 Sell 8.04 217,728 1,750,533 382,996 02/03/21
Ketchum Steven B Chief Scientific Off.. Chief Scientific Officer Jan 29 Option 2.4 278,237 667,769 809,741 01/29/21
Ketchum Steven B Chief Scientific Off.. Chief Scientific Officer Jan 29 Sell 8.01 421,629 3,377,248 388,112 01/29/21
THERO JOHN F President and CEO President and CEO Nov 12 Option 3.4 750,000 2,550,000 3,306,405 11/12/20
THERO JOHN F President and CEO President and CEO Nov 12 Sell 4.1 567,405 2,326,360 2,739,000 11/12/20